HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Stock analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Unity Biotechnology in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.65) for the year, down from their previous forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2027 earnings at ($0.09) EPS, FY2028 earnings at $0.25 EPS and FY2029 earnings at $0.40 EPS.

Separately, Chardan Capital lowered their price target on shares of Unity Biotechnology from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday.

Unity Biotechnology Price Performance

UBX stock opened at $1.14 on Thursday. The company has a market capitalization of $19.23 million, a P/E ratio of -0.87 and a beta of 1.02. Unity Biotechnology has a 12 month low of $0.94 and a 12 month high of $3.10. The firm’s fifty day simple moving average is $1.87 and its 200-day simple moving average is $1.51.

Hedge Funds Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC increased its position in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 50,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned approximately 0.30% of Unity Biotechnology worth $49,000 as of its most recent filing with the SEC. 29.49% of the stock is owned by institutional investors and hedge funds.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.